ART Advanced Research Technologies Appoints Rik van Heijningen to Lead European Commercialization of Optix Imaging System
November 28 2007 - 7:56AM
Marketwired
MONTREAL, CANADA (TSX: ARA), a Canadian medical device company
and a leader in optical molecular imaging products for the
healthcare and pharmaceutical industries, is pleased to announce
that Mr. Rik van Heijningen has joined the Company as Director of
European Commercial Operations, Preclinical Imaging. With over 15
years of top-level sales, marketing, and management experience
behind him, Mr. van Heijningen will lead the implementation of a
commercial team to support the current and future Optix� customer
base in Europe. His primary responsibility is to implement a
results-oriented sales, service, and technical support team to grow
market share for ART's preclinical imaging products. Prior to
joining ART, Mr. van Heijningen was Vice President Commercial
Operations at Kreatech Biotechnology BV, and held various
leadership positions at Invitrogen BV and Dynal Biotech ASA, where
he distinguished himself as a customer-focused manager.
"We are very pleased with our ability to recruit a person of Mr.
van Heijningen's caliber to the ART team. His strong track record
of developing and supporting a high technology user base gives us
full confidence that he will lead ART's direct commercial effort
effectively in Europe," said Sebastien Gignac, President and CEO of
ART.
Dino DiCamillo, ART's Vice President of Global Sales and
Marketing, Preclinical Imaging, added: "The appointment of Mr. van
Heijningen is a critical step in the implementation of our
commercial strategy of distributing our preclinical molecular
imaging solution directly to the customers in Europe. It is our
intention to provide world class service and application assistance
to enable our European Optix users to fully utilize the potential
of optical imaging in their research program."
Mr. van Heijningen commented: "I am very excited to take on this
opportunity to lead ART's European commercial effort in preclinical
imaging. I had the opportunity to meet many of ART's users at a
recent User Meeting organized with GE Healthcare in France, and saw
first hand the promise of molecular imaging in basic research, drug
discovery and development. I look forward to continuing to advance
ART's market position and implement a successful team to support
our customer base."
About Rik van Heijningen
Prior to joining ART, Rik van Heijningen spent the last 20 years
in the research, discovery, and preclinical market arena. He has
held diverse sales, marketing, and business leadership roles in
Europe, including Interim Vice President Commercial Operations of
Kreatech Biotechnology BV in The Netherlands, and high ranking
positions of Senior Sales Manager, General Manager for Germany, and
Interim Vice President Tissue Typing, at the various European sites
of Dynal Biotech LLC, where he was an integral part of the
commercial team that ran a business of EUR 12 to 16 million. Mr.
van Heijningen was also a Clinical Oncology Research Technician at
the Academic Hospital of the Free University, Amsterdam, The
Netherlands. Mr. van Heijningen holds a MBA from the University of
Birmingham, England, and has completed university studies in
biochemistry.
About ART
ART Advanced Research Technologies Inc. is a leader in molecular
imaging products for the healthcare and pharmaceutical industries.
ART has developed products in medical imaging, medical diagnostics,
disease research, and drug discovery with the goal of bringing new
and better treatments to patients faster. The Optix� optical
molecular imaging system, designed for monitoring physiological
changes in living systems at the preclinical study phases of new
drugs, is distributed directly by ART in North America and Europe
and is used by industry and academic leaders worldwide. The
SoftScan� optical breast imaging device is designed to improve the
diagnosis and treatment of breast cancer. ART is commercializing
the SoftScan optical medical imaging device via a global strategic
alliance with GE Healthcare, a world leader in mammography and
imaging. Finally, the Fenestra� line of molecular imaging contrast
products provide image enhancement for a wide range of preclinical
Micro CT applications allowing scientists to see greater detail in
their imaging studies, with potential extension into other major
imaging modalities. The distribution of the Fenestra line of
imaging contrast agents is made through GE Healthcare Bio-Science
KK in Japan and is sold directly by the Company in the rest of the
world. ART's shares are listed on the TSX under the ticker symbol
ARA. For more information on ART, visit our website at www.art.ca
.
This press release may contain forward-looking statements
subject to risks and uncertainties that would cause actual events
to differ materially from expectations. These risks and
uncertainties are described in the most recent Annual Information
Form and the financial statements for the year ended December 31,
2006, available on SEDAR (www.sedar.com).
Contacts: ART Advanced Research Technologies Inc. Jacques Bedard
Chief Financial Officer 514-832-0777 jbedard@art.ca www.art.ca
Aclara Resources (TSX:ARA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Aclara Resources (TSX:ARA)
Historical Stock Chart
From Jul 2023 to Jul 2024